- Lofepramine (brand Gamanil) is a tricyclic antidepressant (TCA) licensed in the UK for depression. Its label sets out dosing, warnings and interactions (UK oral suspension SmPC).
- Its defining feature is low toxicity in overdose. In UK deaths data for 1993–1999, lofepramine had 1.3 deaths per million prescriptions (95% CI 0.6 to 2.4), against 38.0 for amitriptyline and 53.3 for dothiepin (dosulepin) (Buckley & McManus, BMJ 2002). NICE's depression guidance advises against routinely starting TCAs in people at significant risk of suicide and excludes lofepramine from that advice (NICE NG222; the NICE page itself could not be opened, so this rests on NHS formulary summaries that quote it).
- It works about as well as other antidepressants in short trials, but the evidence is old. In the publicly funded UK AHEAD trial (327 patients, 12 months), depression-free time was similar for lofepramine, older TCAs and SSRIs, and only 52% of patients were followed up at one year (Peveler et al., NIHR HTA 2005).
- Safer in overdose does not mean free of heart risk. In a NIHR-funded study of 238,963 UK patients, lofepramine was linked to a higher rate of heart attack in the first year (adjusted HR 3.07, 95% CI 1.50 to 6.26). The authors say this may reflect doctors choosing it for people seen as prone to heart problems, and they do not rule out a real drug effect (Coupland et al., BMJ 2016).
- Labels warn of raised liver enzymes, sometimes progressing to hepatitis and jaundice, usually in the first 3 months. Low blood sodium (SIADH), seizures, QT prolongation and the usual TCA side effects such as dry mouth and constipation are also listed (UK SmPC 4.4, 4.8).
- Money trail: lofepramine was developed by Eriksoo and colleagues, with patents assigned to the Swedish company AB Leo (Merck Index entry). The same entry lists Gamanil and Gamonil as Merck KGaA trademarks and Tymelyt as a Lundbeck trademark. Zentiva, a generics company, was bought by private equity firm GTCR from Advent on 9 April 2026 (Zentiva, April 2026). The UK oral suspension is licensed to Essential Pharma, which announced a €900 million recapitalisation in December 2024 (company announcement).
- Evidence grade: Moderate for treating depression (one open-label 2005 comparative trial and older class-level evidence). Strong that it is far less lethal in overdose than other TCAs. Insufficient for panic, older people at low dose and long-term use. Risk for heart, liver, sodium and seizure effects.
Independent evidence review · Prescription medicine
Lofepramine is the tricyclic antidepressant that UK guidance treats as the exception: it is far less likely to kill in overdose than amitriptyline, dosulepin or imipramine, and NICE excludes it from its advice against routinely starting TCAs in people at significant risk of suicide. Its effect on depression looks similar to other antidepressants, but that rests on a small, open-label 2005 comparative trial and older class-level evidence. It still has tricyclic side effects, a liver-enzyme warning, and an unexplained signal for heart attack in one large UK cohort. Our confidence is high on overdose safety, moderate on benefit and low on long-term use.
Lofepramine is a prescription-only medicine. Do not start, stop or change it without your prescriber. It must not be taken with, or within 2 weeks of stopping, an MAOI antidepressant, and it is not for people with recent heart attack, heart block, arrhythmias, mania or severe liver or kidney disease (UK SmPC 4.3). Antidepressants can take weeks to work. The label notes that suicide risk may rise in the early stages of recovery, and that trials showed more suicidal behaviour on antidepressants in adults under 25. Get urgent medical help for yellowing skin or eyes, a fit, fainting, a racing or irregular heartbeat, or new confusion and drowsiness (a possible sign of low sodium). Lower toxicity than other tricyclics does not make an overdose safe. If you are thinking about harming yourself or ending your life, seek help now: call your local emergency services; in the US call or text 988 (Suicide & Crisis Lifeline); in the UK call Samaritans on 116 123; or your local emergency number.
Table of contents
- Evidence summary
- What lofepramine is
- How it works
- What it is prescribed for
- What works and what does not
- Benefits by claim
- Risks and all side effects
- All interactions
- Who should avoid lofepramine
- Dosage and how to take it
- Follow the money: who makes it and who funded the evidence
- Related research
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict | Strength |
|---|---|---|---|---|
| Lofepramine is much less lethal in overdose than other TCAs | UK 1993–1999: 9 single-drug deaths over about 7.2 million prescriptions, 1.3 deaths per million (95% CI 0.6 to 2.4). Amitriptyline 38.0, dothiepin 53.3. | Buckley & McManus, BMJ 2002 | "Funding: None"; UK data; authors' base not re-checked | Strong |
| The overdose advantage holds across studies | Systematic review of 30 mortality reports: lofepramine "had the lowest risk of death in overdose" of all TCAs studied. | Taylor et al., 2024 | No funding; lead author declared speaker fees from Janssen, Servier, Otsuka and Lundbeck and research funding from Janssen, Lundbeck and BMS | Strong |
| It treats depression as well as other antidepressants | AHEAD trial, 327 UK primary-care patients, 12 months: depression-free weeks 24.6 (lofepramine), 25.3 (older TCAs), 28.3 (SSRIs); no significant difference. | Kendrick et al., BJPsych 2006 | NIHR Health Technology Assessment programme | Moderate |
| TCAs as a class beat placebo | 103 placebo-controlled TCA trials, 10,590 people: pooled HDRS-17 difference −3.77 (95% CI −5.91 to −1.63). Lofepramine-specific trial inclusion not checked. | Kamp et al., BMJ Mental Health 2024 | Funding not verified | Weak (class-level; high risk of bias) |
| Heart attack risk in routine use | 238,963 UK patients aged 20–64: first-year myocardial infarction HR 3.07 (1.50 to 6.26) vs no antidepressant; Authors say selective prescribing may explain this. | Coupland et al., BMJ 2016 | NIHR School for Primary Care Research | Risk (uncertain cause) |
| Seizure risk | Same cohort: epilepsy/seizures HR 3.09 (1.73 to 5.50); about 1 extra case per 138 people treated for 5 years. | Hill et al., BMC Psychiatry 2015 | NIHR School for Primary Care Research | Risk |
| Liver enzyme rises | Labels list raised liver enzymes, sometimes progressing to hepatitis and jaundice, usually within 3 months. | UK SmPC 4.8 | Regulator-approved label | Risk |
Independent evidence and credibility scorecard
Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.
| Source | Who funds it | Country | Independence tier (1–4) | Credibility (A–D) | Why it would tell the truth / residual bias |
|---|---|---|---|---|---|
| NICE NG222 (2022) | UK Department of Health and Social Care | UK | 1 | A | No product to sell; must justify cost to the NHS. Its lofepramine exception is about overdose safety, not proof that lofepramine works better. |
| UK oral suspension SmPC (emc) | Licence holder Essential Pharma; MHRA-approved label | UK | 1 | A for warnings | Warnings, contraindications and dosing are legally required. Irish SmPC not re-checked. |
| AHEAD trial (Peveler 2005; Kendrick 2006) | NIHR HTA programme | UK | 2 | B+ | Publicly commissioned head-to-head trial. Open-label, 52% follow-up at one year, author declarations not re-checked. |
| Buckley & McManus, BMJ 2002 | No funding | UK data (authors' base not re-checked) | 2 | B+ | Uses official death and prescription counts. Observational: drugs seen as "safer" may be given to higher-risk people, which the authors acknowledge. |
| Coupland et al., BMJ 2016 | NIHR | UK | 2 | B+ | Very large real-world cohort. Lofepramine results rest on few events, and confounding by indication is possible, although the authors' baseline comparison did not show it. |
| Hill et al., BMC Psychiatry 2015 | NIHR | UK | 2 | B | Same database and team; the authors warn of residual confounding and indication bias. |
| Kamp et al., BMJ Mental Health 2024 | Not verified | Not verified | 2 | B | Pools TCA trials as a class; lofepramine-specific trial count not checked. |
| Taylor et al., 2024 | No funding | Not verified | 3 | B | Lead author declared speaker fees and research funding from several drug companies, including Lundbeck. |
Our sources cluster heavily in the UK, because lofepramine is mainly a UK medicine. There is almost no recent evidence from other countries.
What lofepramine is
Lofepramine is a tricyclic antidepressant.
- Forms: a 70 mg per 5 ml oral suspension (UK SmPC). The 2025/26 NHS split between tablets and suspension could not be verified in this check.
- Brand names: Gamanil is a brand name that UK trial materials also used (AHEAD trial report). The Merck Index lists other historical trademarks: Amplit (Daiichi), Gamonil (Merck KGaA), Timelit (UCB) and Tymelyt (Lundbeck) (Merck Index entry).
- Legal status: Prescription only in the UK. We did not confirm US status from an official database in this review; secondary sources say it is not available in the United States.
How it works
Its mechanism and pharmacokinetics were not re-checked in this review. Desipramine is scored separately in UK fatal-toxicity data at 200.9 deaths per million prescriptions (95% CI 92.0 to 381.6), while lofepramine scored 1.3 (Buckley & McManus 2002).
What it is prescribed for
| Region | Licensed indication | Source |
|---|---|---|
| UK (oral suspension) | Treatment of symptoms of depressive illness. | UK SmPC 4.1 |
Where NICE places it
- People at risk of suicide: NICE asks prescribers to take toxicity in overdose into account and not to routinely start TCAs, except lofepramine, because TCAs carry the greatest overdose risk (NICE NG222).
- Choosing an antidepressant: NICE says SSRIs should be considered the first choice for most people, and that TCAs are dangerous in overdose, "although lofepramine has the best safety profile". The same wording appears for chronic depression and for switching after a poor response (NICE NG222).
Lofepramine is now a niche drug in the UK. We could not verify current NHS prescribing volumes in this check.
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Treating depression in adults | WORKS | Equal to SSRIs and older TCAs in the open-label AHEAD trial (Kendrick et al. 2006); TCAs as a class beat placebo in pooled trials (Kamp et al. 2024) | Lofepramine-only placebo trials could not be re-checked; AHEAD was open-label |
| Safer in overdose than other tricyclics | WORKS | Lowest fatal toxicity of all TCAs in several UK datasets (Buckley; Taylor) | Observational; not a reason to keep large supplies at home |
Benefits by claim
Does lofepramine work for depression?
Probably, to a similar degree as other antidepressants, but on thin and dated evidence. The head-to-head AHEAD trial found no significant difference between lofepramine and older TCAs or SSRIs over a year (Kendrick et al. 2006). Pooled trials of TCAs as a class against placebo show a modest benefit, but lofepramine-specific placebo trials from the 1980s could not be re-checked.
Kamp and colleagues pooled 103 placebo or active-placebo-controlled TCA trials with 10,590 people. The pooled effect was 3.77 points on the 17-item Hamilton scale (95% CI −5.91 to −1.63), just above the 3-point threshold the authors set, and all results were rated at high risk of bias (Kamp et al. 2024).
Is it as good as an SSRI?
The best head-to-head evidence is the publicly funded AHEAD trial in UK primary care. People with a new episode of depression were randomised to an older TCA, an SSRI or lofepramine and followed for a year. Depression-free weeks were 24.6 with lofepramine, 25.3 with older TCAs and 28.3 with SSRIs: not significantly different. Cost-effectiveness analysis favoured SSRIs as first choice, with a probability of up to 0.6 (Kendrick et al. 2006). The weak points were open-label design and that only 52% of patients were followed up at one year (Peveler et al. 2005).
Is it better tolerated than other tricyclics?
We could not verify side-effect comparisons from the early trials, so no tolerability advantage over older tricyclics is claimed here.
Panic and anxiety
We found no verified controlled trial data for panic disorder, so no benefit is claimed here.
Older people
The UK label says elderly patients may respond to lower doses in some cases (UK SmPC 4.2). We found no verified trial data on older adults.
When the first antidepressant has not worked
No verified augmentation data for lofepramine were found in this review.
Risks and all side effects
- Heart rhythm: tachycardia, conduction disorders, worsening heart failure, QT prolongation and arrhythmias including torsades de pointes. (UK SmPC 4.4, 4.8).
- Liver: raised liver enzymes, "sometimes progressing to clinical hepatitis and jaundice", usually within the first 3 months.
- Low sodium: inappropriate antidiuretic hormone secretion (SIADH) causing hyponatraemia. The UK label says to consider it in anyone who becomes drowsy, confused or has a fit (UK SmPC 4.4).
- Blood: isolated reports of agranulocytosis, pancytopenia and thrombocytopenia. Blood counts should be considered, especially with a history of blood disorders (UK SmPC 4.4).
- Seizures: a UK cohort found a higher rate of epilepsy or seizures (see Heart and seizure risk).
- Mood: suicidal thoughts and behaviour, and switching into hypomania or mania in bipolar illness.
Other side effects listed
Dry mouth, constipation, sweating and other anticholinergic effects are the usual tricyclic side effects. Like other TCAs and SSRIs, lofepramine is linked to a higher risk of bone fractures in people aged 50 and over in observational studies (UK SmPC 4.8). The full UK list was not checked line by line here.
How much do the liver warnings matter?
We found no modern study measuring how often lofepramine causes clinically important liver injury.
Heart and seizure risk in routine care
Lofepramine's reputation for safety is mainly about overdose. In ordinary use, the large NIHR-funded QResearch cohort (Coupland et al. 2016) found a higher rate of first-year heart attack on lofepramine (adjusted HR 3.07, 95% CI 1.50 to 6.26), based on 8 events. The authors noted that doctors may prefer lofepramine for people already thought prone to heart problems, which could create this signal. They also reported lower baseline coronary heart disease in lofepramine users than in amitriptyline users (1.1% vs 2.1%), and said the finding could reflect a real risk at usual doses. They also reported an arrhythmia signal; we could not re-check its figures. The same team reported a seizure signal (HR 3.09, 95% CI 1.73 to 5.50; about one extra case for every 138 people treated over five years) (Hill et al. 2015). A 2024 systematic review likewise listed lofepramine with amitriptyline and nortriptyline as associated with greater in-use cardiac risk (Taylor et al. 2024).
Overdose
Both labels state that reported overdoses of 0.7 g to 6.72 g showed "no serious sequelae directly attributable" to lofepramine, though overdose can still cause seizures, QT prolongation and arrhythmias (UK SmPC 4.9). Using England and Wales data for 1993–1995, Mason et al. (2000) estimated one fatality per 233,700 lofepramine treatment episodes, against one per 8,130 for TCAs overall and one per 411,800 for SSRIs. Lofepramine did not differ significantly from SSRIs (P = 0.35), and its confidence interval is very wide because few deaths were recorded.
None of this makes a lofepramine overdose safe, especially when mixed with alcohol or other drugs. Any suspected overdose needs emergency care.
Stopping and withdrawal
The labels advise avoiding abrupt withdrawal unless essential, because symptoms such as insomnia, irritability and excessive sweating can occur (UK SmPC 4.4). Any reduction should be planned with the prescriber.
All interactions
The following are checked against the UK label (UK SmPC 4.5). Other entries in the full label were not verified here.
| Interacting medicine or substance | What can happen | Label position |
|---|---|---|
| MAOI antidepressants (e.g. phenelzine) | Serious reactions | Contraindicated with or within 2 weeks of stopping (UK SmPC 4.3, 4.5) |
| Amiodarone, terfenadine | Ventricular arrhythmias | Avoid (UK SmPC 4.5) |
| Adrenaline, ephedrine and other sympathomimetic agents | Heart and blood-pressure effects | Should not be given together (UK SmPC 4.5) |
| Alcohol and other CNS depressants (e.g. barbiturates, anaesthetics) | Effects potentiated | Caution; tell the anaesthetist (UK SmPC 4.5) |
| Fluvoxamine, fluoxetine | Raise lofepramine levels | Caution (UK SmPC 4.5) |
| Diltiazem, verapamil, cimetidine | Raise lofepramine levels | Caution (UK SmPC 4.5) |
| Rifampicin | Lowers lofepramine levels | Caution (UK SmPC 4.5) |
Ask a pharmacist before combining any serotonergic supplement with an antidepressant.
Who should avoid lofepramine
Contraindications
The labels say lofepramine must not be used by people who are allergic to it or to dibenzazepines, or who have mania, severe liver or kidney impairment, heart block, cardiac arrhythmias, are recovering from a heart attack, have untreated narrow-angle glaucoma, an enlarged prostate with urinary retention, or are at risk of paralytic ileus. It must not be given during acute poisoning with alcohol, sleeping pills, painkillers or psychiatric drugs, or in acute delirium (UK SmPC 4.3).
Use with care
The UK label advises caution in impaired liver or renal function (UK SmPC 4.4). The oral suspension contains 395 mg of alcohol per 5 ml, plus sorbitol and maltitol, so people with hereditary fructose intolerance should ask their prescriber first.
Children and teenagers
Not recommended for children (UK SmPC 4.2).
Pregnancy
The UK label says the administration of lofepramine in pregnancy and during breastfeeding is not advised unless there are compelling medical reasons. Neonates whose mothers took tricyclics in late pregnancy have had withdrawal symptoms, respiratory depression and agitation (UK SmPC 4.6).
Breastfeeding
Lofepramine is excreted in breast milk, and the label advises against use during breastfeeding unless the benefits clearly outweigh the risks (UK SmPC 4.6). We found no published lofepramine-specific breastfeeding data.
Liver and kidney disease
Contraindicated in severe impairment and used with caution in milder disease. Elimination may be reduced in liver disease (UK SmPC 5.2).
Dosage and how to take it
These are label doses for information only. They are not instructions; the prescriber sets the dose.
- Adults (label): usually 70 mg twice daily (140 mg) or three times daily (210 mg), depending on response.
- Older adults: some may respond to lower doses.
- Under 18: not recommended.
How to take it and how long it takes
Product quality and supply
We found no UK quality recall of lofepramine.
Follow the money: who makes it and who funded the evidence
Who made it, and who sells it now
- Developer: lofepramine was prepared by E. Eriksoo and colleagues, with British and US patents assigned to the Swedish company AB Leo; its manufacturer code was Leo 640 (Merck Index entry).
- Branded era: Gamanil and Gamonil are listed as Merck KGaA (Germany) trademarks (Merck Index entry).
- Owner of the generics company: GTCR completed its purchase of Zentiva, a generics company, from Advent on 9 April 2026 (Zentiva company news, April 2026). We could not confirm which company holds the Irish Gamanil licence, so no licence holder is named for Ireland.
- UK oral suspension: licence PL 41871/0019, held by Essential Pharma Ltd of Egham, Surrey (UK SmPC). Essential Pharma announced a €900 million recapitalisation in December 2024 through a Gyrus Capital continuation vehicle led by AlpInvest, with financing from Sixth Street (company announcement via GlobeNewswire).
Documented integrity events
Who funded the evidence
- Efficacy trials: the lofepramine trials we found date from 1982 to 1996, when it was a branded product. The PubMed records for the key placebo-controlled trials carry no funding statements, and we could not verify their sponsors. We removed the 1991 pooled analysis (Kerihuel & Dreyfus) from our grading because we could not confirm its author affiliation or funding.
- Public money: the strongest comparative trial (AHEAD) was commissioned by the NHS R&D Health Technology Assessment programme. Its author declarations were not re-checked in this review (Peveler et al. 2005). The Coupland cohort was NIHR-funded.
- Overdose data: the key fatal-toxicity analysis had no funding (Buckley & McManus 2002). The 2024 review was unfunded, though its lead author declared industry fees from other companies (Taylor et al. 2024).
Research funding at a glance
8 sources graded. The counts below are the independence tiers assigned in the scorecard above. They count sources, not funding amounts or evidence quality.
Public funding alone does not prove independence, and commercial funding alone does not prove a claim false. Named funders, countries and relationships are in the scorecard and source notes.
What this means: lofepramine's benefit for depression was established in the branded era and has never been re-tested in a large modern placebo-controlled trial. Its overdose advantage, by contrast, comes from public mortality statistics analysed by unfunded or publicly funded researchers, and it is the reason NICE treats it differently. The cardiac and seizure signals also come from public money, and they deserve more attention than they usually get.
Related research
Other Pure City Research medicine reviews and guides:
- Dosulepin: prescribing restrictions, overdose risk and withdrawal
- Amitriptyline: independent evidence
- Nortriptyline: independent evidence
- Sertraline: independent evidence
- Mirtazapine: independent evidence
- Major depressive disorder
- Depression in older adults
- Perinatal and postpartum depression
- Stress, depression and heart disease
- Antidepressant withdrawal and dependence
- Mental health crisis warning signs
Frequently asked questions
Is lofepramine safer than other tricyclic antidepressants?
In overdose, yes, by a wide margin: 1.3 deaths per million prescriptions against 38.0 for amitriptyline in UK data (Buckley & McManus 2002). In everyday use it still carries tricyclic heart, seizure and anticholinergic risks, and one large cohort linked it to more heart attacks in the first year (Coupland 2016).
Why does NICE make an exception for lofepramine?
NICE advises not routinely starting TCAs in people at significant risk of suicide because of overdose danger, but excludes lofepramine from that advice and says it "has the best safety profile" among TCAs (NICE NG222).
Is lofepramine available in the United States?
Secondary sources say it is not available in the United States. We did not confirm this from an official database in this review. It is mainly used in the UK.
Does lofepramine cause weight gain or sleepiness?
Drowsiness, confusion and low sodium are listed warning signs (UK SmPC 4.4). We did not verify weight effects.
Does lofepramine affect the liver?
It can raise liver enzymes, sometimes progressing to hepatitis and jaundice, usually in the first 3 months (UK SmPC 4.8). We found no modern study measuring how often this causes clinical liver injury.
Can lofepramine be taken while breastfeeding?
The UK label says lofepramine is excreted in breast milk and that use during breastfeeding is not advised unless the benefits clearly outweigh the risks. Discuss it with the prescriber.
How long does lofepramine take to work?
Antidepressants often take several weeks to work, and early review matters.
Is it safe to drink alcohol on lofepramine?
The UK label says lofepramine effects can be potentiated by alcohol and other CNS depressants (UK SmPC 4.5). The oral suspension itself contains alcohol.
Can lofepramine be stopped suddenly?
The labels advise against abrupt withdrawal because of insomnia, irritability and sweating (UK SmPC 4.4). Any change should be planned with the prescriber.
Sources and funding notes
What we could not verify: We checked the UK SmPC on emc for dosing, contraindications, MAOI, amiodarone and other listed interactions, alcohol content, hyponatraemia, blood, liver, pregnancy, breastfeeding, withdrawal and overdose wording; the Buckley and McManus 2002, Taylor 2024, Coupland 2016, Hill 2015, Kamp 2024, AHEAD and Mason 2000 figures; the Zentiva and Essential Pharma announcements; and the NICE "except lofepramine" and "best safety profile" wording through NHS formulary summaries, because the NICE page itself could not be opened. We could not verify the Irish HPRA SmPC and patient leaflet, the full UK interaction list beyond the items above, the 1980s placebo and comparative trials (Feighner, Rickels, Pugh and others), the panic, older-adult, augmentation, liver and multiple sclerosis trials, the Hawton 2010 figures, the NHS prescribing counts and costs, the 2010 Japanese recall, and the SPS and UKTIS pages. Claims that depended only on these have been removed. We did not find a Cochrane review specific to lofepramine.
- emc: Lofepramine 70 mg/5 ml Oral Suspension SmPC (revised September 2024) — MHRA-approved label; licence holder Essential Pharma Ltd.
- NICE NG222: Depression in adults (2022 PDF copy) — UK guideline; funded by the Department of Health and Social Care.
- Peveler R et al. Health Technol Assess 2005 (full report) — AHEAD randomised trial; NHS R&D HTA programme; authors declared various pharma ties.
- Kendrick T et al. Br J Psychiatry 2006 — AHEAD cost-effectiveness paper; same funder.
- Buckley NA, McManus PR. BMJ 2002 — fatal toxicity index; "Funding: None".
- Taylor D et al. Ther Adv Psychopharmacol 2024 (full text) — systematic review; no funding; lead author declared industry fees.
- Coupland C et al. BMJ 2016 (full text) — cardiovascular cohort; NIHR School for Primary Care Research.
- Hill T et al. BMC Psychiatry 2015 (full text) — seizure cohort; NIHR School for Primary Care Research.
- Kamp CB et al. BMJ Ment Health 2024 (full text) — TCA meta-analysis; no support for the work; author interests declared.
- Mason J et al. Br J Gen Pract 2000 — fatal toxicity per treatment episode; funding not verified.
- openFDA check: not run successfully in this review; US status rests on secondary sources.
- Merck Index entry: Lofepramine (third-party mirror) — patents and trademarks.
- Zentiva: GTCR completes acquisition (April 2026); Essential Pharma recapitalisation (December 2024) — company statements.
Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.